COO of Monte Rosa (NASDAQ: GLUE) sells 2,176 shares under 10b5-1 plan

Rhea-AI Filing Summary

Monte Rosa Therapeutics Chief Operating Officer Jennifer Champoux reported an option exercise and related share sale under a pre-arranged plan. She exercised stock options for 2,176 shares of common stock at $3.98 per share and sold 2,176 shares in an open-market transaction at $19.00 per share, all on June 17, 2026 pursuant to a Rule 10b5-1 trading plan adopted on February 19, 2026. Following these transactions, she directly owns 62,371 common shares and holds 33,473 stock options.

Insider Trade Summary 10b5-1

Net Seller: 2,176 shares ($41,344)

Net Sell 3 txns

Insider Champoux Jennifer

Role Chief Operating Officer

Sold 2,176 shs ($41K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	2,176	$0.00	--
Exercise	Common Stock	2,176	$3.98	$9K
Sale	Common Stock	2,176	$19.00	$41K

Holdings After Transaction: Stock Option (Right to Buy) — 33,473 shares (Direct, null); Common Stock — 64,547 shares (Direct, null)

Footnotes (1)

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026. 25% of this option vested on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Shares sold: 2,176 shares Sale price: $19.00 per share Options exercised: 2,176 shares +4 more

7 metrics

Shares sold 2,176 shares Open-market sale of common stock on June 17, 2026

Sale price $19.00 per share Price for 2,176 common shares sold

Options exercised 2,176 shares Stock options exercised into common stock

Option exercise price $3.98 per share Exercise price for stock options converted

Shares owned after transaction 62,371 shares Direct common stock holdings post-transaction

Options remaining 33,473 options Stock Option (Right to Buy) position after exercise

Option expiration date June 3, 2034 Expiration of Stock Option (Right to Buy)

Key Terms

Rule 10b5-1 trading plan, Stock Option (Right to Buy, open-market sale, Exercise or conversion of derivative security, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (Right to Buy financial

"Stock Option (Right to Buy), transaction_shares 2176.0000, underlying_security_title Common Stock"

open-market sale financial

"transaction_action open-market sale, transaction_code_description Sale in open market or private transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Exercise or conversion of derivative security financial

"transaction_code_description Exercise or conversion of derivative security"

vesting in 36 substantially equal monthly installments financial

"with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Champoux Jennifer

(Last) (First) (Middle)

MONTE ROSA THERAPEUTICS, INC.

321 HARRISON AVENUE, SUITE 900

(Street)

BOSTON MASSACHUSETTS 02118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2026		M(1)		2,176	A	$3.98	64,547	D
Common Stock	06/17/2026		S(1)		2,176	D	$19	62,371	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.98	06/17/2026		M(1)			2,176	(2)	06/03/2034	Common Stock	2,176	$0	33,473	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026.

2. 25% of this option vested on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Phil Nickson, Attorney-in-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Monte Rosa Therapeutics (GLUE) COO Jennifer Champoux report on this Form 4?

She reported an option exercise and matching share sale. Champoux exercised stock options for 2,176 Monte Rosa common shares at $3.98 each and sold 2,176 shares at $19.00 each, all on June 17, 2026, under a Rule 10b5-1 plan.

How many Monte Rosa (GLUE) shares did the COO sell and at what price?

She sold 2,176 shares of Monte Rosa common stock at $19.00 per share. The transaction is classified as an open-market sale and occurred on June 17, 2026, as part of the activity disclosed in this Form 4 filing.

What options did the Monte Rosa (GLUE) COO exercise in this filing?

She exercised stock options covering 2,176 shares of common stock at a $3.98 exercise price. These options are part of a grant where 25% vested on May 28, 2025, with the remaining portion vesting in 36 substantially equal monthly installments thereafter.

How many Monte Rosa (GLUE) shares does the COO hold after these transactions?

After the reported transactions, Champoux directly owns 62,371 shares of Monte Rosa common stock. This figure reflects her position following the June 17, 2026 option exercise and corresponding open-market sale disclosed in the Form 4 report.

How many stock options does the Monte Rosa (GLUE) COO retain and when do they expire?

Following the exercise, she retains 33,473 stock options described as “Stock Option (Right to Buy).” These options relate to Monte Rosa common stock and carry an expiration date of June 3, 2034, as shown in the derivative transaction details.

Was the Monte Rosa (GLUE) COO’s share sale part of a Rule 10b5-1 plan?

Yes, the transactions were executed under a Rule 10b5-1 trading plan. The footnotes state that the plan was adopted by the reporting person on February 19, 2026, indicating the trades were pre-arranged rather than discretionary market-timing decisions.